Status:

TERMINATED

Comparing the Ongoing Pregnancy Rate for Vitrification of Day-4 Morula With Day-5 Blast

Lead Sponsor:

Egyptian Foundation of Reproductive Endocrinology

Collaborating Sponsors:

Al Hayat ICSI Centre of Alexandria, Egypt

Agial IVF/ICSI Unit of Alexandria, Egypt

Conditions:

Infertility

Eligibility:

FEMALE

18-40 years

Phase:

NA

Brief Summary

Comparing the vitrification at Day-4 (morula stage) with the blastocyst stage vitrification outcomes with the transfer of all day 5 after warming seems need evaluation. To the best of our knowledge, t...

Detailed Description

Vitrification of human embryos has been a paradigm-shifting procedure for higher survival rate compared with the slow freezing protocol. The evidence is scarce to support superior results for vitrifyi...

Eligibility Criteria

Inclusion

  • Women age of ≥ 18 to ≤ 40
  • BMI of ≤ 31
  • Normal responder (≥ 12 antral follicle count (AFC) during basal ultrasound examination) or hyper responder
  • The freeze-all groups including PCOS, OHSS, or high Progesterone at trigger day
  • Women who have ≥ 1 year of primary or secondary infertility
  • Tubal factor (unilateral, bilateral obstruction or salpingectomy)
  • Fresh semen ejaculates but not frozen or surgically retrieved sperm
  • Male factor: oligoasthenozoospermia but not globozoospermia or pinhead sperm
  • Women who are undergoing their first or second ICSI attempts with a previously successful attempt
  • Women who undergo only freeze-all embryo
  • Freeze-all for poor endometrium at the fresh cycle
  • Freeze-all due to abnormal endometrial findings such as polyp or myoma with a decision for freeze all for surgical correction.
  • Women who have normal endometrial thickness (≥ 8) and echo-pattern at the time of progesterone start in the proposed vitrified warmed cycle

Exclusion

  • Women who have uncorrectable uterine pathology or abnormality including submucous myoma
  • Women or their husbands who have abnormal karyotyping
  • Women with a history of recurrent abortions or repeated implantation failures
  • Women who have uncontrolled diabetes
  • Women with diagnosed or undiagnosed liver or renal disease
  • Women who had a history of malignancy or borderline pathology
  • Women who will not meet the inclusion criteria
  • Women who will refuse to participate in the study
  • Women with endometriosis
  • Patient undergoing PGS or PGD
  • Surgically retrieved, frozen-thawed and pinpoint sperm or globozoospermia
  • Adenomyosis
  • Severe medical condition

Key Trial Info

Start Date :

January 15 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2020

Estimated Enrollment :

53 Patients enrolled

Trial Details

Trial ID

NCT03787901

Start Date

January 15 2019

End Date

June 1 2020

Last Update

June 14 2022

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Agial

Alexandria, Egypt, 12345

2

Al Hayat ICSI Centre of Alexandria

Alexandria, Egypt, 12345

3

AlMadina IVF and ICSI Centre

Alexandria, Egypt, 12345

4

Rahem Fertility Centre of Zagazig

Zagazig, Egypt, 12345